Invested in the next 

generation of

regenerative medicine

Discover

Fortuna Fix

The process of regeneration developed by Fortuna Fix is based on the Axolotl Salamander’s well documented ability to regenerate. 

Read more

TWO MAIN TECHNOLOGY PLATFORMS

1. Directly Reprogrammed Neural Precursor Cells

drNPCs: multipotent cells of the neural lineage produced by direct reprogramming. Directly reprogrammed neural precursor cells (drNPC) are made by reprogramming somatic cells which are the everyday cells that make up the body.  The technology is akin to replacing the software of a cell (which is the hardware). This allows skin cells or blood cells, for example, to be become neural precursor cells, which in turn can differentiate to neurons, astrocytes, oligodendrocytes to rebuild neural tissue (Central Nervous System and Spinal Cord). The drNPCs are autologous and their manufacturing is fully automated.

2. Regeneration
Matrix™

Regeneration Matrix™ is  a unique self-assembling 3-dimensional biomaterial with intricate physical characteristics that mimic the matrix in regenerating tissues. Placing Regeneration Matrix™ in a site of injury kick-starts the regeneration process in damaged or injured tissue. Regeneration Matrix™  promotes angiogenesis and has an ability to prevent scar tissue formation and the growth of tumour cells.

Neuro-regeneration

moving toward the clinic

Rebuilding neural tissue and restoring functionality with therapeutic stem cells that are: 

- custom-designed to address the underlying pathology of each condition 

- personalised to each patient (autologous)

Lead programs involve transplantation of directly reprogrammed autologous neural precursor cells:

  • A9 dopaminergic precursor cells for Parkinson's Disease
  • Motor neuron and oligodendrocyte precursor cells for Spinal Cord Injury

latest news

Fortuna Fix Announces the Appointment of Madhavan Balachandran to the Board of Directors; Jan-Eric Ahlfors, CEO of Fortuna Fix Inc., to present at IABS/CIRM 4th Cell Therapy Conference on June 6, 2018 in Los Angeles

Fortuna Fix is focusing on manufacturing and appoints Mr Balachandran to the Board of Directors. CEO Jan-Eric Ahlfors was invited to present at the 4th Stem Cell conference hosted by IABS and CIRM on manufacturing.

Continue reading →

Fortuna Fix Presenting at Unite to Cure: The Fourth International Vatican Conference — How Science, Technology and 21st Century Medicine Will Impact Culture and Society

LONDON, April 26, 2018 (Newswire.com) - Fortuna Fix Ltd (“Fortuna”), is a private regenerative medicine company aiming to be the first to bring to the clinic the patients' own (autologous) directly reprogrammed neural precursor cells (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma. On Friday, April 27, 2018, Jan-Eric Ahlfors, CEO and CSO of Fortuna, will be presenting at the Fourth International Vatican Conference “Unite to Cure”. Fortuna’s directly reprogrammed cell technology platform will feature in a session entitled “The Pharmacy of the Future – Stem Cells and Cardiovascular, Pulmonary and Neurodegenerative Diseases”.

Continue reading →

Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA’s comprehensive new policy approach to facilitating the development of innovative regenerative medicine products to improve human health

Commissioner statement on FDA’s comprehensive regenerative medicine policy framework

Continue reading →

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

LONDON AND MONTREAL, November 8, 2017 (Newswire.com) - Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma.

Continue reading →

Amgen Leaps Into the World of Regenerative Medicine With New Investment

Backed by Amgen Ventures, privately-held regenerative medicine company Fortuna Fix secured $25 million in funding to push its autologous stem cell treatments for Parkinson’s disease and spinal cord injuries into the clinic.

Continue reading →